Concepedia

Shengqiang Xu

SX

Statistics

Publications

4

Citations

202

H-Index

4

Active since

2010

Affiliations

Harvard University(Current)

Brigham and Women's Hospital

Shengqiang Xu is an author at Harvard University specializing in oncology, molecular oncology, and life sciences.

Publications per year

2010–2022

4

Publications

4

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Jieqiong Liu, Ying Wang, Zhenluan Tian et al. · Nature Communications · 2022 · 101 citations · Full text

Medicine, Oncology, Pharmacology +16

RPL41, a Small Ribosomal Peptide Deregulated in Tumors, Is Essential for Mitosis and Centrosome Integrity

Shan Wang, Jianmin Huang, Jié He et al. · Neoplasia · 2010 · 44 citations · Full text

Life Sciences, Cell Biology, Oncology +11

Ribosomal protein RPL41 induces rapid degradation of ATF4, a transcription factor critical for tumour cell survival in stress

Shengqiang Xu, Xiaoxian Zhang, Jie He et al. · The Journal of Pathology · 2011 · 44 citations

Life Sciences, Cancer Biology, Molecular Biology +14

AIF Downregulation and Its Interaction with STK3 in Renal Cell Carcinoma

Shengqiang Xu, Hongjin Wu, Huan Nie et al. · PLoS ONE · 2014 · 13 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

1–4 of 4